出典: meddic


Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/10/17 01:34:37」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Multiple sclerosis: review of eye movement disorders and update of disease-modifying therapies.
  • Amezcua L1, Morrow MJ, Jirawuthiworavong GV.
  • Current opinion in ophthalmology.Curr Opin Ophthalmol.2015 Nov;26(6):534-9. doi: 10.1097/ICU.0000000000000211.
  • PURPOSE OF REVIEW: To review important eye movement disorders in multiple sclerosis (MS) and update the ophthalmologist on disease-modifying therapies in MS, from the perspective of expert neurologists.RECENT FINDINGS: A large study confirmed that eye movement abnormalities in MS can be commonly ide
  • PMID 26397889
  • Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
  • Dallari S1, Franciotta D2, Carluccio S1, Signorini L1, Gastaldi M2, Colombo E2, Bergamaschi R2, Elia F1, Villani S1, Ferrante P3, Delbue S4.
  • Journal of neuroimmunology.J Neuroimmunol.2015 Oct 15;287:76-9. doi: 10.1016/j.jneuroim.2015.08.010. Epub 2015 Aug 14.
  • Natalizumab is a humanized monoclonal antibody against the α4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of
  • PMID 26439965
  • Natalizumab modulates the humoral response against HERV-Wenv73-88 in a follow-up study of Multiple Sclerosis patients.
  • Arru G1, Caggiu E1, Leoni S2, Mameli G1, Pugliatti M2, Sechi GP2, Sechi LA3.
  • Journal of the neurological sciences.J Neurol Sci.2015 Oct 15;357(1-2):106-8. doi: 10.1016/j.jns.2015.07.007. Epub 2015 Jul 8.
  • Multiple Sclerosis (MS) is a heterogeneous disorder of the central nervous system (CNS) that begins as an inflammatory autoimmune disorder mediated by auto-reactive lymphocyte followed by microglial activation and chronic degeneration. The etiology of Multiple Sclerosis (MS) is unknown but several d
  • PMID 26190523


  • 多発性硬化症の治療--再発抑制薬の現状と新薬治療の展望 (AYUMI 多発性硬化症と視神経脊髄炎)
  • Rescue treatments for multiple sclerosis (第50回日本神経学会総会(2009年)) -- (招待講演 多発性硬化症の臨床と病理のトピックス)
  • 臨床神経学 49(11), 708-714, 2009-11-01
  • NAID 10026290604
  • 再認可されたnatalizumabによる多発性硬化症再発予防


Visit the official TYSABRI® (natalizumab) website to learn more about how it can help manage your condition. ... Indication TYSABRI ® (natalizumab) is a prescription medicine used to treat adults with relapsing forms of Multiple ...
インテグリンは,細胞接着蛋白質(フィブロネクチン,ビトロネクチン,コラーゲンなど10数種類)に対する細胞表面上の受容体蛋白の総称である.αサブユニットとβサブユニットが1対1に非共有結合で会合したαβヘテロダイマーに ...


Mechanism of Action: NatalizumabNatalizumabFigure 1NATALIZUMAB 300MG TYSABRINatalizumabFig 2.